Gidazepam
Gidazepam is a benzodiazepine prodrug developed in the former Soviet Union and used medically in some post-Soviet states as an anxiolytic. It is metabolised to the long-acting active compound desalkylgidazepam. On the grey market it is sold as a research chemical; human data come mainly from regional clinical use.
01 Overview
Gidazepam (hydazepam) is an atypical benzodiazepine designed as a daytime anxiolytic with a relatively activating profile at low doses. It is a prodrug: its effects are largely mediated by the metabolite desalkylgidazepam, which is very long-acting. It has been used clinically in countries such as Ukraine and Russia, giving it more human exposure than most designer benzodiazepines, though it remains outside Western pharmacopoeias.
Reported effects include anxiolysis with comparatively less sedation than classical benzodiazepines at therapeutic doses, though sedation dominates at higher doses. Because its active metabolite accumulates, repeated dosing readily produces prolonged sedation and next-day impairment. Dependence and withdrawal risks are those of the benzodiazepine class.
02 Mechanism
Prodrug metabolised to desalkylgidazepam, a positive allosteric modulator at the GABA-A benzodiazepine site.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 20–50 mg | Oral | Regional clinical dosing; the active metabolite accumulates over days. |
| Strong | 50–100 mg | Oral | Higher doses become clearly sedating. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| AnxiolysisReduction of anxiety, reported in regional clinical use as relatively non-sedating at low doses. | Moderate | Observational | |
| SedationDrowsiness that increases with dose and with metabolite accumulation. | Dose-dependent | Observational | |
| Muscle relaxationMild reduction in muscle tension. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Dependence and withdrawalRegular use produces tolerance and dependence; withdrawal can include rebound anxiety and seizures. | Severe | Common with regular use | Observational | |
| Prolonged sedation and blackoutsAccumulation of the long-acting metabolite can cause carryover sedation and amnesia. | Moderate | With accumulation | Observational | |
| Additive respiratory depressionDangerous in combination with opioids or alcohol. | Life-threatening | With CNS depressants | Observational |